Adial Pharmaceuticals Inc (ADIL) USD 0.001

Sell:$0.74Buy:$0.75$0.04 (4.61%)

Prices delayed by at least 15 minutes
Sell:$0.74
Buy:$0.75
Change:$0.04 (4.61%)
Prices delayed by at least 15 minutes
Sell:$0.74
Buy:$0.75
Change:$0.04 (4.61%)
Prices delayed by at least 15 minutes

Company Information

About this company

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.

Key people

Cary J. Claiborne
President, Chief Executive Officer, Director
Vinay Shah
Chief Financial Officer
Tony Goodman
Chief Operating Officer, Director
Kevin Schuyler
Lead Independent Chairman of the Board
J. Kermit Anderson
Independent Director
Robertson H. Gilliland
Independent Director
James W. Newman
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US00688A2050
  • Market cap
    $5.03m
  • Employees
    4
  • Shares in issue
    6.47m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.